Every Form 4 that Taysha Gene Therapies, Inc. (TSHA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TSHA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TSHA filings page.
Taysha Gene Therapies, Inc. director and officer Nagendran Sukumar reported an open-market sale of 200,000 shares of common stock on July 10, 2026 at a weighted average price of $6.24 per share. The shares were sold in multiple trades between $5.99 and $6.52 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. Following the transaction, Sukumar holds 936,410 shares of common stock directly.
Taysha Gene Therapies director John A. Stalfort III reported equity awards in the company’s common stock. He received 21,335 shares through a restricted stock unit award at a price of $0.00 per share. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to his continued service as a director.
He was also granted stock options for 42,671 shares of common stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, he holds 1,176,559 shares of common stock directly and 884,290 shares indirectly through the John A. Stalfort III 2018 Irrevocable Trust.
Taysha Gene Therapies director Phillip B. Donenberg reported equity compensation grants. He received 21,335 shares of Common Stock as a restricted stock unit award at no purchase price. These RSUs vest on the earlier of June 1, 2027 or the next annual stockholders meeting, if he continues serving as a director.
He was also granted a stock option covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these grants, he directly holds 241,289 shares of Common Stock.
Taysha Gene Therapies director Alison S. Long reported equity compensation awards. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award that will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, contingent on her continued board service.
She was also granted stock options covering 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 stock options.
Taysha Gene Therapies director Laura Sepp-Lorenzino reported equity awards consisting of restricted stock units and stock options. She received 21,335 shares of Common Stock as a restricted stock unit (RSU) award, which will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to her continued service as a director. She was also granted a stock option for 42,671 shares of Common Stock at an exercise price of $5.97 per share, expiring on June 1, 2036. Following these awards, she directly holds 127,178 shares of Common Stock and 42,671 options.
Taysha Gene Therapies, Inc. President and Head of R&D Nagendran Sukumar exercised employee stock options for 19,021 shares of common stock at an exercise price of $1.71 per share and sold 200,000 common shares at a weighted average price of $4.46 per share. The sale occurred in multiple trades between $4.335 and $4.625 and was made pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2025. Following these transactions, he directly holds 1,136,410 shares of common stock and 455,920 stock options.
Taysha Gene Therapies Chief Financial Officer Kamran Alam reported a small insider sale tied to taxes. On February 4, 2026, he sold 1,655 shares of common stock at $4.52 per share. The footnote explains this was a mandatory sell-to-cover transaction to pay income taxes from restricted stock unit vesting. After the sale, Alam directly held 1,442,131 shares of Taysha Gene Therapies common stock.
Taysha Gene Therapies President and Head of R&D Nagendran Sukumar reported routine share sales tied to tax withholding. On January 23, 2026, he sold 89,132 shares of common stock at a weighted average price of $4.75. On January 26, 2026, he sold an additional 26,918 shares at a weighted average price of $4.61.
According to the disclosure, these transactions were part of a mandatory sell-to-cover arrangement used solely to satisfy income tax liabilities from vesting restricted stock unit awards. After the reported sales, Sukumar beneficially owned 1,317,389 shares of Taysha Gene Therapies common stock directly.
Taysha Gene Therapies, Inc. Chief Executive Officer and director Nolan Sean P. reported routine stock sales tied to tax withholding on vested equity. On January 23, 2026, he sold 136,789 shares of common stock at a weighted average price of $4.75, and on January 26, 2026 he sold an additional 41,312 shares at a weighted average price of $4.61. According to the disclosure, these transactions were executed under a mandatory sell-to-cover arrangement to satisfy income tax liabilities from restricted stock unit vesting.
Following these sales, Nolan directly beneficially owned 2,908,257 shares of Taysha common stock and indirectly beneficially owned 1,535,545 shares held through Nolan Capital, LLC, where he serves as President with shared voting and investment power.
Taysha Gene Therapies, Inc. chief financial officer Kamran Alam reported sales of company common stock tied to tax withholding on vested equity awards. On January 23, 2026, he sold 78,968 shares of common stock at a weighted average price of $4.75 per share. On January 26, 2026, he sold an additional 23,849 shares at a weighted average price of $4.61 per share. A footnote states these transactions were part of a mandatory sell-to-cover arrangement to satisfy income tax liabilities from the vesting of restricted stock unit awards. After these transactions, Alam beneficially owned 1,443,786 shares of Taysha common stock directly.
Taysha Gene Therapies, Inc. reported that its Chief Financial Officer, Kamran Alam, received new equity awards. On January 12, 2026 he was granted 359,000 shares of common stock in the form of restricted stock units, which will vest in four equal annual installments beginning on January 12, 2027, as long as he remains in continuous service.
On the same date, he also received an employee stock option to buy 231,000 shares of common stock at an exercise price of $4.86 per share, with 25% vesting on January 12, 2027 and the rest vesting in 36 equal monthly installments, subject to continued service. After these awards, he beneficially owned 1,546,603 shares of common stock directly and 231,000 stock options directly.
Taysha Gene Therapies, Inc. reported new equity awards to its Chief Executive Officer, Nolan Sean P. On January 12, 2026, he received 1,008,000 shares of common stock in the form of a restricted stock unit (RSU) award at a price of $0 per share, increasing his directly held common stock to 3,086,358 shares. The RSUs vest in four equal annual installments beginning on January 12, 2027, conditional on his continued service.
On the same date, he was granted an employee stock option for 648,000 shares of common stock with an exercise price of $4.86 per share, expiring on January 12, 2036. Twenty-five percent of the option vests on January 12, 2027, with the remainder vesting in 36 equal monthly installments thereafter, also subject to continued service. Separately, 1,535,545 shares of common stock are held indirectly through Nolan Capital, LLC, where he has shared voting and investment power.
Taysha Gene Therapies president and head of R&D Nagendran Sukumar reported multiple stock transactions on January 12, 2026. He exercised options for 111,324 shares of common stock at an exercise price of $0.6989 per share and 88,676 shares at $1.71 per share, then sold 200,000 shares of common stock at a weighted average price of $4.71 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025.
After these moves, he directly held 1,006,439 shares of common stock before receiving an additional 427,000 restricted stock units, which increased his reported common stock holdings to 1,433,439 shares. He also received a new employee stock option for 274,000 shares at an exercise price of $4.86 per share, vesting over time starting January 12, 2027.